US Approval for Varenicline Tablets, 0.5 mg and 1 mg
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts less than Nifty Microcap 250 and 4.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare has received approval from the US FDA to market Varenicline Tablets in 0.5 mg and 1 mg strengths in the United States. Varenicline is the generic version of Pfizer's Chantix, a widely used smoking cessation medication. With this approval, the company is now positioned to manufacture and sell this generic drug in the large US market. Specific revenue contribution and launch timelines have not been disclosed in the filing. This adds to Shilpa Medicare's growing portfolio of US-approved generic formulations.
This approval gives Shilpa Medicare entry into the lucrative US smoking cessation generics market, which could support future revenue growth. However, generic competition typically leads to pricing pressure, so the actual revenue impact will depend on market share capture and competition timing.